Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Mankind Pharma is India's fourth-largest pharmaceutical company by domestic sales, specializing in branded generics across chronic and acute therapeutic segments including cardiovascular, anti-diabetic, gastro-intestinal, and anti-infective drugs. The company operates a capital-efficient model with strong rural penetration through 10,000+ field force and distribution across 400,000+ retail outlets, competing primarily in the fragmented Indian domestic market where it holds approximately 4% market share.
Mankind generates revenue by manufacturing and marketing branded generic formulations at significant discounts (30-50%) to multinational pharma brands while maintaining 70%+ gross margins through backward integration in API production, low-cost manufacturing, and efficient field force deployment. Pricing power derives from doctor relationships, brand recall in tier-2/3 cities, and first-mover advantage in launching generic versions of molecules coming off patent. The company operates 12 manufacturing facilities with minimal capex requirements (3-4% of sales) due to oral solid dosage focus, generating high cash conversion.
Domestic formulations growth rate relative to Indian Pharma Market (IPM) growth of 8-10%, driven by prescription volume trends and new product launches
Gross margin trajectory based on API input costs (particularly Chinese API prices) and product mix shift toward higher-margin chronic therapies
Market share gains in key therapeutic segments (cardiovascular 5.2%, anti-diabetic 4.8% current share) versus competitors like Sun Pharma, Cipla, Dr. Reddy's
Regulatory actions by Indian drug pricing authority (NPPA) affecting price controls on essential medicines comprising 20-25% of portfolio
Field force productivity metrics and rural market penetration expansion beyond current 60% coverage
Indian government price control expansion through National List of Essential Medicines (NLEM) affecting 20-25% of current portfolio, with potential ceiling price reductions of 30-50% on controlled drugs
Shift toward online pharmacy channels (currently 5-7% of market) disrupting traditional field-force model and reducing pricing power through price transparency
Increasing regulatory scrutiny on pharmaceutical marketing practices and doctor engagement, potentially limiting prescription influence strategies
Intense competition from 3,000+ Indian pharma companies in branded generics space compressing market share gains, with top 10 players holding only 35% combined share
Aggressive pricing by larger competitors (Sun Pharma, Cipla, Lupin) in high-margin chronic segments eroding Mankind's 30-40% price discount positioning
Multinational pharma companies launching authorized generics at competitive prices in key molecules post-patent expiry
Moderate debt levels at 0.55x D/E with ₹25-30 billion term loans requiring ₹3-4 billion annual debt service, though well-covered by ₹20+ billion operating cash flow
Working capital intensity requiring ₹40-50 billion tied up in inventory (75-90 days) and receivables (30-45 days) creating liquidity demands during high-growth phases
Contingent liabilities from ongoing patent litigation and regulatory compliance matters typical in pharmaceutical industry
low-to-moderate - Pharmaceutical demand is relatively inelastic as healthcare spending is non-discretionary, but acute segment volumes (anti-infectives, pain management representing ~30% of sales) correlate with seasonal illness patterns and economic activity. Chronic therapy demand (cardiovascular, diabetes comprising ~40% of sales) shows minimal GDP sensitivity. Rural demand, representing 40% of sales, exhibits moderate correlation with agricultural income and monsoon performance.
Rising interest rates have minimal direct impact on operations given low debt levels (0.55x D/E) and limited borrowing requirements due to strong cash generation. However, higher rates compress valuation multiples for growth stocks and increase discount rates applied to future earnings. Working capital financing costs (for 90-day inventory and receivables cycle) increase modestly but represent <1% of revenue impact.
Minimal credit exposure as business model involves cash/short-term credit sales to distributors and stockists with 30-45 day payment terms. No significant customer concentration risk given fragmented retail pharmacy channel. Receivables quality remains stable with <2% bad debt historically.
growth - Investors are attracted to 18% revenue growth significantly above Indian pharma market growth, strong domestic market positioning, and cash generation profile. The stock appeals to growth-at-reasonable-price (GARP) investors given 6.1x P/S and 27x EV/EBITDA valuations for high-teens revenue growth. Recent 12-16% underperformance over 6-12 months has attracted value-oriented investors viewing current levels as entry points. Limited dividend yield (~1%) makes this primarily a capital appreciation story.
moderate-to-high - Indian mid-cap pharmaceutical stocks typically exhibit 25-35% annual volatility driven by regulatory announcements, quarterly earnings surprises, and broader emerging market sentiment. Stock shows high correlation (0.7-0.8) with Nifty Pharma Index and moderate correlation (0.5-0.6) with broader Nifty 50. Recent 8% quarterly decline reflects sector-wide concerns about pricing pressure and margin compression rather than company-specific issues.
